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Abstract
Background: Within the health literature, a major goal is to understand distribution of service
utilisation by social location. Given equivalent access, differential incidence leads to an expectation
of differential service utilisation. Cancer incidence is differentially distributed with respect to
socioeconomic status. However, not all jurisdictions have incidence registries, and not all registries
allow linkage with utilisation records. The British Columbia Linked Health Data resource allows
such linkage. Consequently, we examine whether, in the absence of registry data, first
hospitalisation can act as a proxy measure for incidence, and therefore as a measure of need for
service.
Methods: Data are drawn from the British Columbia Linked Health Data resource, and represent
100% of Vancouver Island Health Authority cancer registry and hospital records, 1990–1999.
Hospital separations (discharges) with principal diagnosis ICD-9 codes 140–208 are included, as are
registry records with ICDO-2 codes C00-C97. Non-melanoma skin cancer (173/C44) is excluded.
Lung, colorectal, female breast, and prostate cancers are examined separately. We compare
registry and hospital annual counts and age-sex distributions, and whether the same individuals are
represented in both datasets. Sensitivity, specificity and predictive values are calculated, as is the
kappa statistic for agreement. The registry is designated the gold standard.
Results: For all cancers combined, first hospitalisation counts consistently overestimate registry
incidence counts. From 1995–1999, there is no significant difference between registry and hospital
counts for lung and colorectal cancer (p = 0.42 and p = 0.56, respectively). Age-sex distribution
does not differ for colorectal cancer. Ten-year period sensitivity ranges from 73.0% for prostate
cancer to 84.2% for colorectal cancer; ten-year positive predictive values range from 89.5% for
female breast cancer to 79.35% for prostate cancer. Kappa values are consistently high.
Conclusion: Claims and registry databases overlap with an appreciable proportion of the same
individuals. First hospital separation may be considered a proxy for incidence with reference to
colorectal cancer since 1995. However, to examine equity across cancer health services utilisation,
it is optimal to have access to both hospital and registry files.
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Background
Health service utilisation, equity and incidence
A major focus within the health service utilisation litera-
ture is to understand distribution of health and health
services in the context of equity, that is, distribution with
respect to social location indicators such as socioeco-
nomic status, education and the like (e.g. [1-5]). It is rela-
tively simple to describe health service utilisation over
time; it is less simple to evaluate utilisation equity over
time; the latter necessitates first understanding the distri-
bution of need or requirement for service. That is, if utili-
sation rates of some service decrease over time within
lower income quintiles, is this due to structural access
inequity or is the requirement for those health services
decreasing?
While more difficult with respect to home care or mental
health services (where needs assessments vary depending
on government policy), need for cancer-related health
care services would seem to depend most fundamentally
on incidence itself, a relatively objective state. Cancer inci-
dence has been demonstrated in more than one jurisdic-
tion to be differentially distributed with respect to a
primary social locator, socioeconomic status (e.g. [6-11]),
leading to an expectation of differential service utilisation
across socioeconomic status, even given equivalent access
to service.
However, not all jurisdictions maintain cancer incidence
registries, nor do all existing registries allow linkage with
utilisation records. How might researchers evaluate need
for service in the absence of a cancer registry? First hospi-
talisation may vary with social location, and can be uti-
lised as a measure of access to health services [12]. We
examine here whether first hospitalisation may be used as
a proxy for incidence, or need for service.
Administrative claims data and disease registries
The relationship between disease registries and adminis-
trative claims data, and use of the latter for disease surveil-
lance, has been investigated in several jurisdictions. With
respect to diseases other than cancer, Goldacre and Rob-
erts [13] assessed incidence of acute pancreatitis in Oxford
(UK) on the basis of hospital admissions; they reasoned
that this calculation would yield a good approximation of
true incidence, as almost all people who receive a diagno-
sis of acute pancreatitis will be admitted to hospital. Hux
et al. [14] recently validated a procedure using linked
administrative data from Ontario and the Canadian Insti-
tute for Health Information (CIHI) to determine preva-
lence and incidence of diabetes in Ontario. They conclude
that in a single-payer health care system, administrative
data can provide a population-based opportunity to mon-
itor chronic diseases. In contrast, Taylor [15] evaluated
use of ICD-9 codes in administrative records to calculate
incidence of bile duct injury during laparoscopic cholecys-
tectomy in Ontario (see also comment by Marshall [16]).
Taylor concluded that the clinical significance of the
injury was not captured by the code without reference to
a chart review, and therefore that the incidence of signifi-
cant injury could not be calculated from the administra-
tive records alone, which yielded an inaccurately high
rate.
Do administrative data effectively complement cancer registries?
The question is not new. Morgan and Scott [17] assessed
the performance of the (then) relatively new British
Columbia Cancer Registry with respect to two factors:
first, whether the registry missed an appreciable amount
of hospital cancer separations (discharges); and second,
whether using separations data would increase cancer
incidence reporting. Female breast, bronchus and lung,
and prostate cancer and acute leukemias were examined;
the percent registered of those sampled from the separa-
tions data were 86.3%, 94.4%, 81.9% and 78.9% respec-
tively. The authors concluded that cases missed by the
registry on hospital separation likely would be collected
on death registration, and that including these cases
would shift registry counts upwards by a few percentage
points.
Middleton et al. [18] evaluated hospital-only records for
inclusion in the Northern Ireland Cancer Registry and
conclude that discharge records constitute a valuable
resource that nonetheless requires corroboration prior to
inclusion in the registry. Without the discharge data,
11.5% of final database records would have been missing;
however, without validation procedures, the registry
would have increased inaccurately by 7.5% (from 18,703
to 20,229). In the United States, Wang et al. [19] com-
pared claims data and a cancer registry in their ability to
identify incident breast cancer cases in New Jersey, 1989–
1991, amongst women registered with Medicaid, Medi-
care or the drug assistance program for the elderly
(PAAD). Neither claims data nor the registry identified all
incident cases; however, used in combination more than
90% of incident cases could be identified. The two data
sources used in combination are most critical with respect
to ascertaining subpopulations such as women under 65,
minorities and the poor.
Penberthy et al. [20] examined the use of hospital dis-
charge files to track cancer cases, noting that under-report-
ing remains a problem in central cancer registries. The
study matched records from the Virginia Cancer Registry
to those from state hospital discharge files for 1995. Only
first admissions for an individual were included. Breast,
cervical, colorectal, lung and prostate cancer cases were
examined. A subset of cases was selected to assess positive
predictive value (PPV) of the hospital discharge filesInternational Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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judged by the inpatient medical record. Overall PPV was
94%, with 88% PPV for hospital-only records. This is one
of the few studies where both discharge and registry data-
sets are evaluated simultaneously in reference to an inde-
pendent gold standard. The authors conclude neither
registry nor hospital files completely describe all incident
cancer cases, and careful use of hospital discharge files to
supplement the cancer registry would enhance cancer sur-
veillance.
To what degree do registry and claims datasets describe the same 
individuals?
In New South Wales, Australia, McGeechan et al. [21]
linked hospital and cancer registry datasets for invasive
breast cancer cases in 1992. Ninety-three percent of
records in the cancer registry were successfully linked to
hospital records. Pollock and Vickers [22] examined
colorectal, lung and female breast cancer registrations in
the Thames Cancer Registry (UK) 1991–1994, to deter-
mine which records could be linked to hospital records.
The study evaluated the extent to which death certificate
only registrations could be reduced in the cancer registry.
Sixty-six percent of cancer registry files found matches in
the hospital dataset; for colorectal, lung and female breast
cancer the numbers were, respectively, 72%, 62% and
65%. The authors conclude that cancer registry ascertain-
ment trumps the accuracy of hospital files, which none-
theless can contribute to reducing the proportion of death
certificate only records.
Stang et al. [23] compared agreement amongst linked
Medicare (in-patient) records, cancer registry and death
certificates in Massachusetts from 1986–1990. Kappa val-
ues for agreement were high between hospitalisation and
death certificate data (κ = 0.70), and moderate between
hospitalisation and cancer registry, and death certificates
and cancer registry. With respect to specific cancers, the
authors conclude that site-specific agreements among the
databases were higher for colorectal and respiratory tract
cancers as compared to breast and prostate cancers.
Cooper et al. [24] calculated the sensitivity of Medicare
claims data to identify cancer cases using Surveillance,
Epidemiology and End Results (SEER) Program records,
linked to hospital and other records in SEER-enrolled cit-
ies in the United States. SEER records were designated the
gold standard; breast, colorectal, endometrial, lung, pan-
creatic and prostate cancers were included in the study.
The authors conclude that Medicare claims yield accepta-
bly high sensitivity (up to 94% depending on cancer type
and range of records utilised) in reference to registry data.
In contrast, Koroukian et al. [25] linked Ohio Medicaid
Claims Data from 1997 and 1998 with corresponding
years in the Ohio Cancer Incidence Surveillance System.
The aim was to assess the ability of claims data to correctly
identify incident breast cancers among women aged 40+,
using the OCISS as the gold standard. Overall sensitivity
was 68.7%, with overall PPV 43%.
Can claims data be used to calculate cancer incidence?
Toniolo et al. [26] estimated cancer incidence in a region
of northern Italy from hospital discharge records, linking
hospital to cancer registry records. Results indicated gen-
erally higher incidence rates calculated from hospital as
compared to registry records. The authors attribute this
difference to a number of factors, including the presence
of prevalent cases, errors in coding and multiple hospital
admissions. Nonetheless, they note that for some sites,
such as male lung and colorectal cancers, there is near-
equivalence for both count and age-sex distribution
between the two data sources. Quality of information
seemed lowest in the extreme age groups; the authors sug-
gest this is due to lack of hospitalisation amongst older
patients, and small sample fluctuations in the youngest
age groups. They conclude that hospital files yield accept-
able incidence estimates for more frequent cancers (here,
esophageal, stomach, colorectal, pancreatic and lung can-
cers) using truncated age groups 35–74. Similarly, Huff et
al. [27] report that hospital discharge data from the
Chronic Disease Surveillance System in Maine for lung,
cervical and female cancer consistently overestimated
annual counts and disease rates in relation to cancer reg-
istry records. Prevalent cases may have been partially
responsible for the annual count excess, but the difference
persisted once records were linked across years to calculate
aggregate period counts and rates. The proportion of
1987–1988 hospital discharge records that matched can-
cer registry data were 66%, 40% and 77% for lung, cervi-
cal and breast cancer respectively. The authors note that
variation in admitting practises over time and area might
have resulted in observed discrepancies between registry
and hospital data, and that cases reported to the registry
may have been incomplete.
In the absence of hospital-based cancer registries in
France, Couris et al [28] proposed a system to utilise
claims data to generate valid incidence measures. Simi-
larly, Leung et al. [29] developed an algorithm to correctly
identify incident breast cancer cases from women enrolled
in a California (US) health maintenance organisation
from 1994–1996; the authors conclude that claims data
may be used to identify incident breast cancer cases.
Finally, Pearson et al. [30] discuss the challenge of using
multiple data sources to identify all those individuals, and
only those individuals, with cancer. They conclude that
problems with sensitivity and positive predictive value
limit the usefulness of claims data for identifying incident
cancer cases, and while the American cancer registry sys-
tem is not comprehensive, cancer registries represent the
best bet for incident case identification.International Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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Summary
Administrative claims databases are being used to study
disease occurrence and distribution; these data are best
used in conjunction with available disease registries.
However, not all jurisdictions have cancer registries; nor,
where there are registries, do these necessarily allow link-
age with utilisation data. In addition, researchers do not
always have access to all data sources. Huff et al. [27] state
that "...hospital discharge data will be better suited to
tracking disease occurrence where multiple admissions
for a single individual may be accurately identified, varia-
bility in provider practise with respect to hospitalisation is
minimal, and access to care is consistent" (p.81). These
conditions are reasonably well met with respect to the
data analysed here, given the provenance of the data
source (below), and the provisions of the Canadian uni-
versal single-payer health care system (see also Hux et al.
[14] above). In British Columbia, the British Columbia
Linked Health Data (BCLHD) resource allows hospital
separation records to be individually linked to cancer inci-
dence records from the registry. This resource permits an
assessment of the congruence of hospital separation and
cancer incidence data. We examine here whether first sep-
aration can act as a proxy measure for incidence, and
therefore as a measure of need for service. That is, if we
hypothesize that first hospital cancer separation may be
used as a proxy for cancer incidence, then this is a testable
hypothesis within the British Columbia context.
Methods
Data source
Data were drawn from the British Columbia Linked
Health Data (BCLHD) resource, an administrative health
data repository for health services records included within
the provincially-funded health services plan, for example,
hospital separations, physician services, continuing care
and other services, and including the British Columbia
Cancer Registry (Chamberlayne et al. [31]). These data are
accessible to researchers through the British Columbia
Ministry of Health; the resource is compiled and distrib-
uted by the University of British Columbia Centre for
Health Services and Policy Research (CHSPR) Health
Information Development Unit [32]. CHSPR generates
unique study identification numbers for individuals at the
time of the data draw; these numbers are consistent across
linkable datasets. Use of the BCLHD for this project was
approved by BC Ministry of Health, BCLHD Data Stew-
ards and the University of Victoria Human Research Ethics
Committee.
The British Columbia Cancer Incidence Registry was
established in 1969 and is maintained at the British
Columbia Cancer Agency (BCCA). The registry records
population-based cancer incidence and mortality, with
associated demographic and personal information, for all
residents of British Columbia [33]. Incident cancers are
classified in accordance with International Classification
of Diseases for Oncology-Second Revision (ICD0-2)
codes. Multiple primary cancers attributable to a single
individual are maintained as separate records. A number
of sources contribute to the registry, including the Cancer
Agency itself and hospitals; incidence records are also pro-
duced from death registrations.
Hospital separation records are generated each time an
individual is discharged from hospital, whether treated as
an in- or out-patient. Hospital files may include multiple
separations attributed to a single individual. Up to sixteen
diagnoses are included on each separation record, using
International Classification of Diseases, Revision 9 (ICD-
9) codes; the principal diagnosis is that deemed most
responsible for the hospital stay. In the following analy-
ses, where first separations are specified, these designate
the initial appearance of a study identification number in
the defined dataset.
The study utilised cancer registry and hospital separations
datasets representing a 100% draw for the Vancouver
Island Health Authority (VIHA) within British Columbia.
This Health Authority includes Vancouver Island, the Gulf
Islands and a section of coastal British Columbia. VIHA
mid-year population size over the time period ranged
from 588,441 in 1990 to 690,879 in 1999 [34].
Calendar years 1990 through 1999 are present for cancer
registry data; fiscal years 1989–1990 through 1999–2000
for hospital data. Hospital records dated 1989 and 2000
were excluded from the analysis; separations then span
the same time period as the registry.
Hospital separations with principal diagnoses indicating
malignant neoplasms were included in the analyses,
excluding non-melanoma skin cancers (ICD-9 173); sim-
ilarly, non-melanoma skin cancer (ICDO-2 C44) was
excluded from cancer registry records. Radiotherapy and
chemotherapy hospital separations were excluded from
the analysis as ICD-9 codes for radiotherapy and chemo-
therapy do not indicate type of cancer. Hence, using these
codes from the hospital files for an individual's first occur-
rence would preclude comparing type of cancer coded by
the hospital and by the registry. The effect of eliminating
chemotherapy and radiotherapy codes is to permit a sub-
sequent record for an individual, with a cancer code, to
stand for the individual. Data are ultimately excluded
only for those individuals who have only treatment-coded
records.
Specific cancers examined are lung, colorectal, female
breast, and prostate cancers, defined in accord with
National Cancer Institute of Canada ICD-9 [35] andInternational Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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ICDO-2/3 [36] specifications. See Table 1 for codes used
in the analyses.
Analysis
This paper assesses the extent to which administrative
hospital separation records may be used to measure can-
cer incidence. At base, this is an exercise in counting indi-
viduals across age and sex through the study period. As
hospitals are the main source of information for the can-
cer registry, we expect considerable overlap between the
hospital separations and registry files. Since both registry
and separations files for the region are 100% draws, it is
possible as well to assess regions of exclusivity between
the files. Lacking an independent gold standard, we desig-
nate registry data as the gold standard; the BC Cancer Reg-
istry reports 91.9% case ascertainment completeness for
2001 [33]. Table 2 outlines how individual study identifi-
cation numbers distribute between registry and separa-
tions files. We examine whether annual first counts and
age-sex distributions for hospital separations are signifi-
cantly different from corresponding registry values.
More specifically, and annually, we count the following
with respect to all cancers and specific cancers: 1) all reg-
istry cancers; 2) all hospital cancer separations; 3) unique
study identification numbers in the registry files, and their
corresponding frequencies; and 4) unique study identifi-
cation numbers in the separations files, and their corre-
sponding frequencies. We compare the annual count of
unique study identification numbers in registry and hos-
pital separations files using Pearson's chi-square test for
goodness-of-fit.
We then merge annual registry and separations files by
study identification numbers, selecting for: 1) all cancer
codes; 2) lung cancer only; 3) colorectal cancer only; 4)
female breast cancer only; and 5) prostate cancer only. See
Figure 1 for an outline of the merge procedure. We com-
pare the degree to which the hospital separations report
the same individuals, not simply the same count, as the
registry files, by examining total unique study identifica-
tion numbers, and their distribution between and within
registry, separations and shared domains.
Counts and measures are calculated for annual files, and
for a single file representing the entire ten-year study
period (1990–1999). Total unique counts in the ten-year
file differ from the sum of the annual counts. This is
because individuals may be present either in registry or
separations files more than once within a given year or
across years, and for one or more cancer types. For exam-
ple, in the registry, 2 – 3% of individuals included in the
annual files, and about 6% of those in the ten-year aggre-
gate file, record multiple incident cancers. For the annual
count, an individual is included the first time they appear
each year with respect to the target condition (e.g. lung
cancer); similarly for the ten-year count, each individual is
counted the first time they appear in the ten-year file,
again with respect to the target condition.
We calculate the sensitivity of the separations files judged
by the gold standard of the registry. We also assess specif-
icity, and positive and negative predictive values (PPV,
NPV), of the separations files (see Table 2 for definitions).
We then calculate the kappa (κ) statistic [37,38] for meas-
uring agreement beyond that expected by chance between
the hospital separations and registry files.
For annual files, the mid-year population is the reference
population. A difficulty with the ten-year period calcula-
tions is choosing the correct reference population. It is
neither the mean annual population for the ten-year
period nor the ten-year summed total population. The
correct reference population would be all individuals
present at any time over the ten-year period, a number
between the mean and the summed total population, and
is unknown. We use the ten-year mean population, choos-
ing to err on the side of underestimation. The effect of this
choice is as follows. Neither sensitivity nor positive pre-
dictive value are affected, as the crucial numbers for those
calculations – the registry count, the hospital count and
the distribution of cases between the two–are known
independent of the reference population. Choosing the
smaller reference population does affect specificity, nega-
tive predictive value and kappa; all three will be underes-
timated using this assumption.
Table 1: Classification codes.
Category Hospital separations : ICD-9 Cancer registry : ICDO-2
All cancers 140–208, excluding 173 C00-C97, excluding C44
Lung cancer 162 C33-C34
Colorectal cancer 153–154, 159.0 C18-C21, C26.0
Female breast cancer 174 C50
Prostate cancer 185 C61
Cancers are defined in accord with the National Cancer Institute of Canada specifications [35,36]. Non-melanoma skin cancer is excluded from 
hospital and registry data; chemotherapy and radiotherapy representing first separation are excluded from the hospital records.International Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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Where registry and hospitalisation are both present but do
not occur within the same calendar year, the ten-year
merge will find the corresponding records, whereas
annual files will miss the match. Consequently, we also
calculate the kappa for agreement between diagnosis year
and separation year amongst shared study identification
numbers in the ten-year file.
Finally, if first hospital cancer separation count is accepta-
ble as proxy incidence, then age-sex structure should be
similar between registry and hospital files. Here we
encounter a peculiar situation. We know the age-sex dis-
tribution of both hospital separations records and those
registry records that successfully merged with the hospital
separations files. We do not know the age-sex distribution
of the cancer registry file itself, since neither sex nor age at
diagnosis were available from the BCLHD cancer registry
dataset [32]. Instead, and as an approximation, we use
projected age-sex cancer incidence counts for the Vancou-
ver Island Health Authority in 2003 [33], and compare
1999 first separations data to that projection. We also
assess the age-sex distribution of successfully merged reg-
istry records compared to that of summed annual age-sex
counts for first hospital separations. In both cases we
employ Pearson's goodness-of-fit test, using expected pro-
portions generated in the former case by the projected
incidence counts, and in the latter case by first separa-
tions.
All data were maintained and analysed using SAS v8.0
[39]. Sensitivity, specificity, positive and negative predic-
tive values and their confidence intervals were calculated
using GraphPad Instat [40]; goodness-of-fit tests for distri-
butions were calculated using GraphPad [41]. Probability
values for goodness-of-fit tests for counts were calculated
using S-Plus v6.2 [42]. Confidence intervals for registry
counts (95% CI) were calculated with Pezzullo [43].
Results and discussion
Study period total counts for the cancer registry and hos-
pital separations are reported in Table 3. Approximately
82% of records in the VIHA registry dataset were contrib-
uted by hospital sources, with 6% of cases reported by the
BC Cancer Agency itself, 3% by death registrations and 1%
by other sources (including out of province cancer regis-
tries and private physicians); 8% were missing sources.
Pathology was the primary method of confirmation, for
84% of records in the registry. All records in the VIHA can-
cer registry were associated with a VIHA postal code of res-
idence. With respect to hospital separations, 90.8% of
records were reported from hospitals within the Vancou-
ver Island Health Authority, and 99.2% of unique study
identification numbers in the hospital cancer separations
dataset were associated with a VIHA postal code of resi-
dence at the time of separation.
Table 4 reports unique study identification numbers from
registry and hospital datasets. The 34,023 registry records
are generated by 31,976 individuals over the ten-year
study period. The mean number of primary cancers per
individual is 1.06 (standard deviation (SD) 0.26), the
mode is one, and the range is between 1 and 4. The max-
imum number of incident cancers within any year
reported for any one individual is three. The 60,255 can-
cer separations are generated by 31,203 individuals over
the ten-year study period, with a mean of 1.93 (SD 1.55),
Table 2: Distribution of unique study identification numbers between cancer registry and hospital separations.
Study identification numbers Cancer registry present Cancer registry absent Totals
Hospital separations present ab ( a  +  b )
Hospital separations absent cd ( c  +  d )
Total (a + c) (b + d) (a + b + c + d)
Notes.
1. Total unique study identification numbers = (a + b + c)
2. All study identification numbers from BCCA cancer incidence registry = (a + c)
3. All study identification numbers from hospital cancer separations = (a + b)
4. Shared study identification numbers between BCCA registry and hospital separations = a
5. Study identification numbers only in the BCCA registry = b
6. Study identification numbers only in hospital separations = c
7. Reference population used for annual calculations is the mid-year VIHA population = (a + b + c + d)
8. Count "d" represents the balance of the VIHA mid-year population appearing in neither registry nor separations records
9. In the case of the 1990–1999 aggregate file, the ten-year mean mid-year population is designated as the reference population; see discussion in 
text for effect of this assumption
10. The cancer registry is taken as the gold standard
Measures.
1. Similarity = [(a + b)/(a + c)]
2. Sensitivity = [a/(a + c)]
3. Specificity = [d/(b + d)]
4. Positive predictive value = [a/(a + b)]
5. Negative predictive value = [d/(c + d)]International Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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mode of one, and a range from 1 to 34 separations. The
maximum number of separations within any given year
reported for any one individual is twenty-two.
Figure 2 illustrates annual hospital counts as percent of
annual registry counts for all cancers, and lung, colorectal,
female breast and prostate cancers. Figure 2a depicts total
counts, including multiple records attributed to single
individuals. The curves are generated by the relationship
between the number of incident cancer diagnoses and the
pattern of initial and subsequent hospitalisations. Assum-
ing a relationship between the registry and hospital
records, where multiple hospitalisations characterise a
cancer, the curve will lie above the 100% line; where the
cancer does not always result in hospitalisation, the curve
will dip below 100%. Actual values range from 221% (all
cancers and lung cancer in 1990) to 95% (prostate cancer
in 1999). Figure 2b represents annual first counts, and
depicts similarity in counts for unique study identification
numbers in the respective datasets. All values start the dec-
ade above 100%; similarity coalesces around 100% in the
latter half of the decade.
Procedure for merging registry and hospital files Figure 1
Procedure for merging registry and hospital files.
Total study identification numbers
Cancer registry 
Select records by cancer site diagnosis 
e.g. lung cancer, ICDO-2 C33 - C34 
Cancer registry 
Given only lung cancer records, select first occurrence 
of any given study identification number 
Hospital separations 
Select records by separation principal diagnosis 
e.g. lung cancer, ICD-9 162 
Merge files by study identification number
Registry–only 
study identification numbers 
Shared study identification numbers 
Separations-only 
study identification numbers 
Hospital separations 
Given only lung cancer records, select first occurrence 
of any given study identification number International Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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Figure 3 illustrates annual counts for unique study identi-
fication numbers for the registry and hospital separations,
with 95% confidence intervals for the registry counts. The
hospital all-cancers count consistently overestimates the
registry count over the study period. The same cannot be
said of the individual cancers. Pearson chi-square good-
ness-of-fit tests across the entire ten-year study period
indicate significant differences in annual counts between
the datasets for all cancers and the specific cancers exam-
ined. However, using the sequence of counts for only the
second half of the decade (1995–1999), these tests indi-
cate annual counts for lung and colorectal cancer are not
significantly different between registry and hospital files
(p = 0.42 and p = 0.56, respectively); counts in the second
half of the decade are significantly different for all cancers,
and female breast and prostate cancer.
Figure 4 illustrates the results of merging registry and first
cancer separations files by unique study identification
number for all cancers and, separately, lung, colorectal,
female breast and prostate cancer. There are six curves for
each cancer: the total number of unique study identifica-
tion numbers present across both registry and separations
datasets; study identification numbers from the registry
dataset, and the cancer separations dataset; study identifi-
cation numbers present in the shared dataset, that is, suc-
cessfully matched study identification numbers; and
study identification numbers in the registry only, and in
the separations file only. Figure 5 illustrates sensitivity
between registry and first separations files, that is, the per-
cent of registry unique study identification numbers
shared annually with hospital separations files. Annual
values for sensitivity for all cancers combined and specific
cancers begin the decade clustered closely around 80%,
and decline (except for colorectal cancer) and disperse
thereafter. Sensitivity is greatest for colorectal and female
breast cancer.
From the foregoing it will be clear that not all individuals
in the cancer separations file are present in the registry,
and vice versa; in addition it is clear from the sensitivity
values that not all individuals are first hospitalised for a
specific cancer during the same year in which their diag-
nosis is recorded in the registry.
Table 5 details ten-year period values for sensitivity and
specificity, and positive and negative predictive values of
separations to the registry gold standard; kappa values for
agreement between registry and separations records; and,
given the subset of study identification numbers shared
Table 3: VIHA cancer registry and hospital cancer separations, count of all records.
Registry All Cancers Lung Colorectal Female Breast Prostate
1990–1999 34,023 4,505 4,379 5,101 5,613
1990 2,830 388 392 415 496
1991 3,133 423 390 498 545
1992 3,241 457 415 459 574
1993 3,555 454 429 467 718
1994 3,271 408 461 495 532
1995 3,290 461 409 483 419
1996 3,510 469 446 568 529
1997 3,691 486 486 590 572
1998 3,627 460 475 557 559
1999 3,875 499 476 569 669
Hospital All Cancers Lung Colorectal Female Breast Prostate
1990–1999 60,255 7,362 6,216 6,341 7,660
1990 6,260 857 610 578 942
1991 6,382 911 580 664 913
1992 6,432 895 573 660 1,024
1993 6,533 844 617 592 998
1994 5,892 643 625 631 719
1995 5,797 699 578 627 593
1996 5,733 685 580 682 584
1997 5,975 677 682 646 628
1998 5,636 576 665 619 620
1999 5,615 575 706 642 639
Cancer registry counts include all incident primary cancers reported to the registry, excluding C44, non-melanoma skin cancer. Hospital cancer 
separations include all separations with principal diagnoses as ICD-9 code 140 through 208, excluding 173, non-melanoma skin cancer, and 
excluding chemotherapy and radiotherapy separations.International Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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between datasets over the aggregate ten year period, kappa
values for agreement between year of diagnosis in the reg-
istry and year of separation from the hospital file. Except
for sensitivity above, annual values for each of these meas-
ures are not shown; they are available on request to the
authors.
Registry and separation records with a single study identi-
fication number that do not occur in the same year will be
matched in the ten-year file. Ten-year sensitivity ranges
from 73.0% for prostate cancer to 84.2% for colorectal
cancer. Recall that hospitals are the main source for cancer
diagnoses in the registry, for approximately 82% of
records. All sensitivity values other than prostate cancer
approach this level, while colorectal cancer exceeds it. If
an individual is present in the hospital dataset, and if 82%
of registry records originate from hospitals, why might
sensitivity drop below this level?
In fact, using all first hospital separations for the study
period, that is, including all principal diagnoses, not just
cancer diagnoses, the sensitivity of the ten-year hospital
file with respect to the cancer registry is 96.5% (95% CI
96.3%–96.7%). So, the first part of the explanation for
lower than expected sensitivity lies with the fact that while
nearly all individuals present in the cancer registry are also
present in the complete hospital separations file, not all of
them are hospitalised recording a principal diagnosis of
cancer.
An additional part of the explanation will reside with the
study period itself. Where separations-only study identifi-
cation numbers represent registry cases recorded prior to
1990, that is, where they constitute prevalent cancers, they
will not appear in the registry during the study period, and
consequently their study identification numbers will fail
to find a match. For example, approximately twenty-eight
percent of both ten-year all cancers combined and pros-
tate cancer, and 26% of colorectal cancer, study identifica-
tion numbers found only in separations files occur in
1990. Hence, prevalent cases will account for some of the
lower than expected sensitivity.
Table 4: VIHA cancer registry and hospital cancer separations summary statistics.
Registry n1 mean2 SD3 minimum4 maximum5
1990–1999 31,976 1.06 0.26 1 4
1990 2,780 1.02 0.13 1 2
1991 3,054 1.03 0.16 1 3
1992 3,179 1.02 0.14 1 3
1993 3,493 1.02 0.14 1 3
1994 3,210 1.02 0.14 1 2
1995 3,231 1.02 0.14 1 3
1996 3,423 1.03 0.17 1 3
1997 3,616 1.02 0.14 1 2
1998 3,538 1.03 0.16 1 3
1999 3,781 1.02 0.16 1 3
Hospital n1 mean2 SD3 minimum4 maximum5
1990–1999 31,203 1.93 1.55 1 34
1990 4,031 1.55 1.10 1 22
1991 4,150 1.54 1.00 1 15
1992 4,252 1.51 0.93 1 12
1993 4,332 1.51 0.90 1 11
1994 4,010 1.47 0.87 1 13
1995 3,939 1.47 0.88 1 16
1996 3,947 1.45 0.91 1 15
1997 4,206 1.42 0.77 1 11
1998 4,067 1.39 0.77 1 15
1999 4,102 1.37 0.72 1 15
For both datasets, the sum of unique study identification numbers each year over the study period will exceed the all-years total, because repeat 
individuals may span a number of years. For example, in the registry there are 110 study identification numbers in the ten-year period with three 
primary cancers, but only 15 record all three within a single year.
1 n total count of unique study identification numbers
2 mean average number of records per unique study identification number
3 SD standard deviation
4 minimum minimum observed records per unique study identification number
5 maximum maximum observed records per unique study identification numberInternational Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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Hospital cancer separations counts as percent of cancer registry counts, 1990–1999 Figure 2
Hospital cancer separations counts as percent of cancer registry counts, 1990–1999. See Table 1 for cancer classi-
fications codes included in the counts.
2a. Total counts – all hospital cancer separations as percent of all registry cases 
2b. Similarity – counts of unique study identification numbers in the annual hospital separations 





lung 220.88% 215.37% 195.84% 185.90% 157.60% 151.63% 146.06% 139.30% 125.22% 115.23%
colorectal 155.61% 148.72% 138.07% 143.82% 135.57% 141.32% 130.04% 140.33% 140.00% 148.32%
female breast 139.28% 133.33% 143.79% 126.77% 127.47% 129.81% 120.07% 109.49% 111.13% 112.83%
prostate 189.92% 167.52% 178.40% 139.00% 135.15% 141.53% 110.40% 109.79% 110.91% 95.52%
all cancers 221.20% 203.70% 198.46% 183.77% 180.13% 176.20% 163.33% 161.88% 155.39% 144.90%





lung 141.3% 138.0% 130.0% 124.2% 108.1% 100.7% 104.7% 102.1% 97.2% 91.8%
colorectal 119.1% 116.2% 108.2% 107.2% 105.0% 104.5% 100.5% 102.3% 103.9% 106.8%
female breast 105.3% 100.6% 109.3% 98.9% 96.5% 94.5% 92.7% 91.2% 93.0% 92.5%
prostate 147.0% 138.2% 137.6% 112.3% 113.9% 119.6% 97.5% 96.7% 97.0% 81.5%
all cancers 145.0% 135.9% 133.8% 124.0% 124.9% 121.9% 115.3% 116.3% 115.0% 108.5%
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999International Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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However, while separations-only prevalent cases do not
appear in the numerator when calculating sensitivity, they
also do not appear in the registry during the study period,
so they do not contribute to the denominator. The final
part of the explanation resides with the group of study
identification numbers that appear in the registry (so they
are counted in the denominator) but do not appear in the
separations files. These represent individuals for whom no
VIHA cancer registry and hospital cancer separations annual first counts Figure 3
VIHA cancer registry and hospital cancer separations annual first counts.
Hospital count 
Registry count 
95% confidence limits 
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hospital cancer separations occur, but who were registered
with a primary cancer during the study period. 54% of
ten-year aggregate registry-only records are 'other' cancers;
lung, colorectal, female breast and prostate cancer con-
tribute 10%, 7%, 11% and 18%, respectively, to the total
number of registry-only study identification numbers. The
distribution for the full ten-year registry dataset for 'other'
and specific cancers is, respectively, 43%, 13%, 12%, 15%
and 17%. There is a significant difference between the reg-
istry-only distribution of cancer types and the expected
distribution from the full registry dataset (chi-square, p <
0.0001); 'other' cancers are over-represented amongst reg-
istry-only records. It might be informative to examine the
age-sex distribution of the registry-only group, for exam-
ple, to see whether they distribute differently from the
shared registry-separations group, but as above, neither
VIHA cancer registry and hospital cancer separations: total, shared and restricted study identification numbers, 1990–1999 Figure 4
VIHA cancer registry and hospital cancer separations: total, shared and restricted study identification num-
bers, 1990–1999. Merge files annually by-cancer study identification number, 1990 through 1999
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age nor sex is available for registry-only study identifica-
tion numbers.
Ten-year specificity and negative predictive vales are uni-
formly high. This is in large part attributable to the size of
the VIHA mid-year reference population and the relative
rarity of a cancer diagnosis. Positive predictive value is var-
iable, and consistently higher in the ten-year file than
annual files across all and specific cancers; it ranges from
89.5% for female breast cancer to 79.35% for prostate
cancer.
Kappa values for agreement on the presence of study iden-
tification number between registry and separations files
range from 0.76, for prostate cancer, to 0.86, for colorectal
cancer. The highest agreement is achieved with colorectal
and female breast cancer, which fall in the 'almost perfect'
range [37]; the remaining cancers, including all cancers
combined, are represented by kappa values indicating
'substantial' agreement.
Kappa values for agreement between diagnosis year and
separation year among those study identification num-
bers shared between registry and separations files are all
above 0.90, in the upper half of the range described by
Landis and Koch [37] as almost perfect. Where the two
years are not identical, hospital separations occur prima-
rily in the year immediately following registry diagnosis
year. For example, for the all-cancers file in diagnosis year
1995, 92% of 2,429 cases were hospitalised in the same
year, 3% were hospitalised prior to 1995, 4% in 1996, and
the remaining 2% were hospitalised from 1997–1999. For
colorectal cancer, of 317 shared study identification num-
bers reported in the registry in 1995, 96% are reported in
the separations file in that year, while 3% are reported
with separations in 1996. Of the two remaining shared
cases, one separated from hospital in 1994 and one in
1997.
As above, we do not have access to registry age-sex struc-
ture from the BCLHD resource. Therefore, we compared
first separations for 1999 to BCCA projections for VIHA
incident cancer cases in 2003 [33]. Relative to the BCCA
projection, first separation distributions by sex are not sig-
nificantly different from the projection for all cancers
combined, or colorectal cancer; lung cancer separations
distribution by sex is significantly different from the pro-
jection with fewer males, and more females, than
Sensitivity: percent of VIHA cancer registry annual count of unique study identification numbers represented by study identifi- cation numbers shared between registry and hospital cancer separations Figure 5
Sensitivity: percent of VIHA cancer registry annual count of unique study identification numbers represented by study identifi-



















lung 80.5% 82.5% 77.9% 76.2% 67.5% 68.8% 70.6% 72.4% 68.8% 68.7%
colorectal 82.2% 84.1% 85.1% 83.5% 79.0% 77.1% 76.1% 80.8% 82.9% 85.1%
female breast 81.8% 81.0% 83.7% 79.3% 78.4% 77.1% 76.9% 75.9% 75.6% 76.5%
prostate 82.1% 83.9% 82.1% 74.8% 69.1% 66.8% 56.7% 57.5% 59.0% 51.9%
all cancers 77.4% 79.2% 77.5% 73.9% 73.1% 74.4% 71.7% 72.4% 71.6% 69.4%
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999International Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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expected (p = 0.02). Only one sex is relevant for female
breast and prostate cancer.
Age distributions are not significantly different for color-
ectal, female breast or prostate cancers for either sex, and
for females for lung cancer. Both sexes for all cancers com-
bined, and males for lung cancer, yield significantly differ-
ent distributions between the hospital separations and
incidence count projections (all cancers, males p =
0.0009, all cancers females p = 0.0001, lung cancer males
p = 0.0045), with a similar pattern of more than expected
separations among 60–79 year olds and fewer than
expected separations among those 80+ years of age.
Finally, we examine ten-year summed annual counts for
successfully merged registry records compared with those
for first separations. There is no significant difference with
respect to distribution by sex amongst lung and colorectal
cancers (and, again, only one sex is relevant for female
breast and prostate cancer). The all-cancers count indi-
cates fewer males and more females than expected
amongst successful registry merged records (p = 0.0001).
Among these merged data, there is no significant differ-
ence in age distribution for lung, colorectal or female
breast cancer. All cancers combined yield significant
results (males p = 0.0001, females p = 0.0012) with more
merged registry records than expected from the hospital
distribution amongst 60–79 year olds, and fewer records
than expected amongst those 80+ years of age. Prostate
cancer age distributions are significantly different (p <
0.0001), with a similar pattern.
Table 5: Sensitivity, specificity, positive predictive value, negative predictive value and agreement (kappa) for ten-year aggregate 
period 1990–1999.
All Cancers Lung Colorectal Female Breast Prostate
Sensitivity 78.58% 77.56% 84.22% 81.60% 73.00%
lower 95% confidence 
limit (CL)
78.12% 76.27% 83.13% 80.48% 71.85%
upper 95% CL 79.04% 78.78% 85.34% 82.66% 74.12%
Specificity 99.02% 99.88% 99.92% 99.86% 99.66%
lower 95% CL 98.99% 99.87% 99.91% 99.84% 99.64%
upper 95% CL 99.05% 99.89% 99.93% 99.87% 99.68%
Positive predictive 
value
80.53% 81.82% 87.07% 89.54% 79.35%
lower 95% CL 80.10% 80.60% 85.96% 88.61% 78.26%
upper 95% CL 80.95% 82.97% 88.09% 90.44% 80.51%
Negative 
predictive value
98.90% 99.85% 99.90% 99.72% 99.52%
lower 95% CL 98.87% 99.84% 99.89% 99.71% 99.50%
upper 95% CL 98.93% 99.86% 99.91% 99.74% 99.54%
Kappa (total) 0.79 0.80 0.86 0.85 0.76
lower 95% CL 0.78 0.79 0.85 0.84 0.75
upper 95% CL 0.79 0.80 0.86 0.86 0.77
Kappa (syear by 
dyear)
0.91 0.93 0.96 0.95 0.91
lower 95% CL 0.91 0.92 0.95 0.95 0.91
upper 95% CL 0.92 0.94 0.97 0.96 0.92
Notes.
1. Cancer registry and hospital cancer separations ten-year aggregate files merged by study identification number, selecting for cancer type and then 
for first occurrence of study identification number.
2. For sensitivity, specificity, positive predictive value and negative predictive value, the cancer registry is designated the gold standard.
3. Kappa (total) measures agreement on study identification numbers between registry and separation records.
4. Kappa (syear by dyear) assesses agreement between separation year and diagnosis year for the subset of shared study identification numbers 
across the ten-year period.
5. Reference population used is the British Columbia midyear population size for both sexes, or single sex with respect to female breast and 
prostate cancer. See text for discussion of choice of reference population for ten-year period.
6. Source for VIHA population figures from 1990 through 1999: BC Stats 2004: http://www.bcstats.gov.bc.ca/data/pop/pop/estspop.htm.
7. Not shown: measures calculated by individual year. These are available on request.International Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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Conclusion
This paper contributes to literature addressing the utility
of administrative claims data in health service utilisation
research, with specific reference to equity, and the ques-
tion of congruence between administrative claims data
and disease registry records. We ask whether first hospital
cancer separations may be used as a proxy measure for
cancer incidence, using the registry file as the gold stand-
ard.
While these data are a sample of the provincial popula-
tion, it is important to note that within the confines of the
Vancouver Island Health Authority these data are not
samples. Excluding administrative and recording error,
they represent all events occurring in the study period. As
such, differences between counts or distributions are true
differences between populations during this period. We
use statistics with associated confidence intervals and
probability values to define the area within which a true
difference is unremarkable, and outside which such a dif-
ference is noteworthy.
Where total counts and age-sex distributions are not sig-
nificantly different, it follows that rates calculated from
those figures will be acceptably equivalent. Does this hold
in the present case? Goodness-of-fit tests across the study
period (1990–1999) indicate significant differences in
annual counts for all cancers and the specific cancers
examined; however, comparison of counts from 1995
through 1999 yield non-significant differences between
registry and separations counts for both lung and colorec-
tal cancer. Distribution by sex between first separations
count and projected registry counts indicate no significant
differences between all-cancers and colorectal cancer (and
the comparison is not applicable for single-sex cancers);
age distributions do not differ for (female) lung, colorec-
tal, female breast or prostate cancer. Colorectal cancer
during the second half of the decade is the only case where
there is no significant difference in count and age-sex dis-
tribution between hospital and registry datasets.
Do the two datasets describe the same individuals? Sensi-
tivity values are highest for colorectal and female breast
cancer, followed by all cancers combined, lung and then
prostate cancer; positive predictive values follow a similar
pattern. Reasons for lower than expected values of sensi-
tivity include prevalent cases, that is, separations-only
records, particularly in the early years of the study period,
and the set of registry-only records not present in the sep-
arations files. This latter group will include both those
individuals diagnosed but not hospitalised, and those
who may have been hospitalised, but not with a cancer
principal diagnosis coded on the separation record.
"Other" cancers are over-represented amongst this group.
We cannot comment on whether the registry-only dataset
has a different age-sex distribution from those registry
records shared with hospital separations, as this informa-
tion is not available to us at present. However, it would
appear that the successfully merged registry records,
shared between registry and separations datasets, for lung,
colorectal and female breast cancer do not represent dif-
ferent age-sex distributions from first hospital separations.
Lastly, values for systematic agreement calculated by
kappa indicate substantial to almost perfect agreement
between registry and hospital files; agreement between
year of diagnosis and separation for individuals shared
between registry and separation files is consistently above
0.90, in the almost perfect range.
In summary, our findings suggest that in spite of the
apparent similarity in count for each of the specific can-
cers examined, first separations are not an acceptable
proxy for most cancer incidence counts, using the cancer
registry as the gold standard. However, the hospital sepa-
rations file acceptably approximates both registry count
and age-sex distribution for colorectal cancer from 1995
through 1999. Additional research may generate correc-
tion factors to translate lung and female breast cancer first
separations to valid incidence measures. If hospital sepa-
rations were regarded as a screening tool for the registry,
they would fail to be acceptable, given low sensitivity
(range 73%–84%), and despite high specificity (>99%).
Ten-year period positive predictive values are all above
80% (save prostate cancer, which falls just short of that
figure); but do not extend above 90%.
This analysis has several limitations. First, we did not have
access to an independent gold standard (for example, see
[20]), and this means that the complete set of unique
study identification numbers was not included in the sen-
sitivity analysis. As a result, we do not know whether our
results and conclusions would shift given a third-party
gold standard. As well, the age-sex comparison was
accomplished only obliquely, as these data were not avail-
able from BCLHD resource cancer registry datasets. In
addition, for ten-year summary measures, the correct ref-
erence population is unknown; however the population
used was chosen to underestimate specific measures, as
discussed above. Finally, these results are calculated from
data generated by a system with universal health care and
first-world technology. Conclusions likely would not
apply in jurisdictions where access to care is limited and/
or treatment or admissions to hospital proceed in a sys-
tematically different manner.
Claims and registry databases overlap with an appreciable
proportion of the same cases. However, there are also
areas of exclusivity, that is, separations-only and registry-
only cases. Even if only because of these exclusive cases,
administrative data may complement but cannot replaceInternational Journal for Equity in Health 2006, 5:12 http://www.equityhealthj.com/content/5/1/12
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the registry. Thus, for analysis of equity across cancer
health services utilisation, it is optimal to have access to
both hospital and registry files. Using the British Colum-
bia Linked Health Data resource, first separation may be
considered a proxy for incidence with reference to color-
ectal cancer since 1995. However, as discussed in the
introduction, first separation itself may be examined as an
indicator of access to cancer-related health services where
incidence remains the primary indicator of need.
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